证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2025-008 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □券商策略会 其他 （国泰海通证券、中金公司、华创证券、信达证券、中泰证券、 华安证券、东北证券、国盛证券 8 家证券联合主持的 2025 年半 年报业绩交流电话会） 参与单位 名称及人员 姓名 易方达基金 华夏基金 天弘基金 浦银安盛基金 博远基金 诺安基金 博道基金 华泰资管 慎知资管 晨壹投资 磐石投资 中昂国际投资 永诚财产保险 太平资管 丹羿投资 英大国际信托 国泰海通证券 中金公司 华创证券 信达证券 中泰证券 华安证券 东北证券 国盛证券 兴业证券 东方证券 国海证券 申万宏源证券 长城国瑞证券 光大证券 长江证券 太平洋证券 招商证券 山西证券 等 46 家机构 56 人 时间 2025 年 8 月 29 日 地点 上海公司会议室 上市公司接 待人员姓名 总经理 杨宏伟 董事会秘书 赖小龙 一、介绍公司 2025 年上半年度经营情况 普蕊斯是一家大数据驱 ...

Financial Performance - In 2024, the company achieved operating revenue of 803.73 million yuan, a year-on-year increase of 5.75% [2] - The net profit attributable to shareholders was 106.43 million yuan, a decrease of 21.01% year-on-year [2] - The net profit excluding non-recurring gains and losses was 83.47 million yuan, down 26.88% year-on-year, primarily due to increased operating costs from hiring new staff [2] - In Q1 2025, operating revenue was 176.47 million yuan, a decline of 4.37% year-on-year [2] - The net profit attributable to shareholders in Q1 2025 was 7.43 million yuan, a decrease of 67.32% year-on-year [2] Contractual and Project Management - The company signed new contracts worth 1 billion yuan, with a total outstanding contract amount of 1.889 billion yuan by the end of 2024, reflecting a year-on-year growth of 0.38% [2] - As of March 31, 2025, the company had undertaken over 3,800 international and domestic SMO projects, with 2,250 projects currently in execution [2] - The company has a total workforce of 4,277 employees and serves over 960 clinical trial institutions across more than 200 cities in China [2] Shareholder Value and Dividends - The total cash dividend for the first half and full year of 2024 was 19.88 million yuan, accounting for 18.68% of the net profit for 2024 [2] - Cumulatively, from 2022 to 2024, the company distributed a total of 40.77 million yuan in cash dividends [2] Industry Insights and Future Outlook - The SMO industry is entering a new development phase, with leading companies expanding client resources and institutional coverage, while smaller firms are gradually exiting the market [3] - In 2024, Chinese pharmaceutical companies achieved a historic breakthrough in licensing-out transactions, totaling 51.9 billion USD, with 4.1 billion USD in upfront payments [3] - The company plans to continue innovating in organizational management and explore the application of AI and new technologies in clinical trial execution [3] Competitive Advantages - The company has strong competitive advantages in various disease areas, including hematological tumors, solid tumors, and rare diseases, having facilitated the launch of 82 new oncology drugs and 14 biosimilars by the end of 2024 [4] - As of December 2024, the company participated in 10 projects related to therapeutic nuclear drugs, 87 TCR projects, 67 ADC projects, and 24 CGT projects [4] - Notable products launched include the world's first approved CLDN18.2 targeted therapy and the first approved oral GLP-1 drug in China [4]